Despite good adherence to high-dose inhaled corticosteroids (ICS) and concomitant long-acting beta agonists (LABA), millions of people with asthma continue to experience exacerbations. What more can patients and clinicians do to reduce the risk of exacerbations? Does the routine use of antibiotics reduce the frequency of exacerbations? This is the question the recently published AMAZES study attempted to answer.